Αποτελέσματα Αναζήτησης
20 Απρ 2021 · Until there is a clearer understanding of the potential effect of local hormone-based therapies on breast cancer recurrence, non-hormonal approaches should be the first-line choices for the management of genitourinary symptoms in breast cancer survivors.
27 Ιουν 2024 · NCI’s risk assessment models for breast cancer, colorectal cancer, and melanoma do this. Other models estimate what we call pure risk: the probability that a woman will get breast cancer if she couldn’t die from anything else.
Risk-assessment tools are used in routine clinical practice to identify women at increased risk of breast cancer and to inform counselling about lifestyle changes, genetic testing, screening timing or modality, and eligibility for risk-reducing drugs or surgery.
14 Ιουλ 2020 · The ongoing development of breast cancer Risk Assessment and Management Programs (RAMPs) presents an opportunity to decrease breast cancer disease incidence with evidence-based interventions.
Breast cancer risk assessment continues to evolve as emerging knowledge of breast cancer risk drivers and modifiers enables better identification of high-risk women who may benefit from increased screening or targeted risk-reduction protocols.
9 Φεβ 2023 · This systematic review aims to characterise studies which compare breast cancer risk assessment tools and assess their ability to stratify screening populations according to (i) absolute risk of breast cancer and (ii) related outcomes of breast cancer risk (expected versus observed incidence of invasive breast cancer, with or without in situ ...
17 Ιουν 2021 · In a review of available breast cancer risk assessment tools, we found the following barriers to informed adoption of endocrine risk reduction: First, it is difficult to understand personal risk and whether the risk of side-effects outweigh the benefits.
